9/17/2021 8:38:44 AM
Merck Gets Positive EU CHMP Opinion For KEYTRUDA In Combination With Chemotherapy
9/7/2021 9:27:02 AM
Illumina Partners With Merck To Develop And Commercialize Tests For Use In Identifying Specific Cancer Mutations
9/7/2021 7:00:55 AM
Merck: KEYTRUDA Approved In China In Combination With Chemotherapy For 1st-Line Treatment Of GEJ Cancer
8/26/2021 7:42:24 AM
Merck's KEYTRUDA Receives Two New Approvals From Japan Pharmaceuticals And Medical Devices Agency
8/25/2021 7:10:32 AM
Merck Announces VAXNEUVANCE Meets Key Immunogenicity And Safety Endpoints In Phase 3 Pivotal Trial
8/18/2021 7:41:55 AM
Werewolf Therapeutics Collaborates With Merck On WTX-124 INDUKINE Program
8/10/2021 7:58:06 AM
Merck: FDA Accepts Review For KEYTRUDA As Single Agent For MSI-H/dMMR Advanced Endometrial Carcinoma
8/10/2021 7:54:36 AM
Merck: FDA Grants Priority Review To SBLA For KEYTRUDA As Adjuvant Therapy In Renal Cell Carcinoma